Ultibro Breezhaler

Ultibro Breezhaler

indacaterol + glycopyrronium

Manufacturer:

Novartis Indonesia
Concise Prescribing Info
Contents
Per cap Indacaterol 110 mcg, glycopyrronium 50 mcg
Indications/Uses
Once daily maintenance bronchodilator treatment to relieve symptoms & reduce exacerbations in patients w/ moderate to severe COPD.
Dosage/Direction for Use
Contraindications
Hypersensitivity. Patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Childn <18 yr.
Special Precautions
Concomitant use w/ long-acting β-agonists or long-acting muscarinic antagonists. Not for the treatment of asthma. Immediately discontinue use if hypersensitivity & paradoxical bronchospasm occurs. Narrow-angle glaucoma, urinary retention, CV disorders (CAD, acute MI, cardiac arrhythmia, HTN), convulsive disorders or thyrotoxicosis, severe renal impairment; hypokalaemia; hyperglycaemia. Pregnancy & lactation.
Adverse Reactions
Upper resp tract infection; nasopharyngitis, UTI, sinusitis, rhinitis; dizziness, headache, cough, oropharyngeal pain including throat irritation, dyspepsia, dental carries, gastroenteritis, musculoskeletal pain, pyrexia & chest pain.
Drug Interactions
β-adrenergic blockers. Anticholinergics. MAOIs, TCAs, drugs known to prolong QT-interval. May potentiate the adverse effects w/ sympathomimetic agents & possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.
ATC Classification
R03AL04 - indacaterol and glycopyrronium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Ultibro Breezhaler inhalation powd cap
Packing/Price
(+ 1 inhaler) 1 × 6's; (+ 1 inhaler) 2 × 6's; (+ 1 inhaler) 5 × 6's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in